Sustainability Direction Performance Indicators (SDPIs)

Astellas believes that our innovations will play a part in improving the sustainability of society. This will build trust from society, which will, in turn, also make Astellas more sustainable.
Expectations for companies that contribute to improving the sustainability of society are increasing. Astellas believes that it is important to meet the expectations from society and will disclose the performance and progress of its sustainability activities appropriately.
We have set the Med-term Priorities for Astellas, Initiatives, and Our Commitments by FY2025 as for the two pillars relating to the 9 material issues and Environmental Sustainability issues in our Sustainability Direction. Based on our commitments, we continue to steadily promote our Sustainability Direction by setting Sustainability Directions Performance Indicators(SDPIs) and disclosing measurable and appropriate tangible actions.

- In principle, the scope of coverage is global, and performance for the period indicated is disclosed
- Information about pharmaceutical products(including products currently in development) which is included in this SDPIs report is not intended to constitute an advertisement or medical advice

1. Creation of new therapies and modalities for the treatment of diseases with high unmet medical needs

Providing solutions that produce better outcomes improves the lives of patients and caregivers around the world and contributes to reducing the overall load on the healthcare system.

^*1 PoC: Proof of Concept/To Confirm efficacy with key clinical data to decide progression to late-stage development
^*2 IND: Investigational New Drug
^*3 Breakthrough Therapy: Food and Drug Administration (FDA) program to facilitate the development and review of drugs for serious or life-threatening diseases.
^*4 Fast Track: A system of Food and Drug Administration (FDA) that provides priority review of new drugs with high therapeutic potential for diseases for which a cure is difficult to achieve.
^*5 PRIME: Priority Medicines / a system implemented by European Medicines Agency (EMA) to strengthen support for the development of medicines for unmet medical needs.
^*6 Priority Review: A system to give priority to medicinal products that meet certain requirements, in addition to medicinal products designated as orphan medicinal products.
^*7 SAKIGAKE Designation System: Japanese system to facilitate the domestic development of innovative medicines for life-threatening diseases for which there is no effective treatment, to ensure the early commercialization of such medicines in Japan, ahead of the rest of the world.

2. Maximize patient access to Astellas’ innovations and enable them to achieve better outcomes

Access to Health is one of the material issues for both society and Astellas. We provide the access to our products for as many patients as possible, and impact more than 36 million people (cumulatively) by 2025 by improving disease awareness, prevention, and access to healthcare services.

^*8 Harnal, VESIcare, Myrbetriq(mirabegron), Prograf, XTANDI,XOSPATA, Evrenzo, PADCEV
^*9 For details, please visit the following website:
Access to Medicines | Astellas Pharma Inc.

3. Contribute to maintaining a sustainable healthcare system through advocating value-based pricing

Advocate for value-based pricing to maintain a sustainable healthcare system.

^*10 KEIDANREN: Japan Business Federation

4. Creating an environment of talent and organizational culture that promotes innovation

Ensure talents with trusted capabilities to deliver innovation and create an organizational culture that fosters innovation.

 ^*11 Span of Control: Number of subordinates managed by one manager

5. Establishment of a more sustainable and resilient value chain

Ensuring the reliable production and supply of safe and effective products even in the case of unpredictable or emergency situations is extremely important. Building a more sustainable and flexible value chain by proactively preparing the manufacturing supply chain, and energy procurement.

^*12 TPLM: Third Party Lifecycle Management
^*13 SRM: Supplier Relationship Management

6. Further improve product quality

Ensure product quality assurance and safety for patients by fostering a "Culture of Quality" and enhancing the customer experience.

^*14 Lean Six Sigma: Lean Six Sigma Program is a pillar of the Culture of Quality Program and a leadership approach to maximize efficiency, create whitespace(resources needed to explore new ideas) and reduce cost within Astellas

7. Achievement of the amount of reasonable reduction of greenhouse gas (GHG) emissions

Astellas has set GHG emission targets consistent with The Paris Agreement and has received the SBT^*15 certification. Aim to achieve by FY2025 the amount of reasonable reduction of GHG emissions target.
［GHG emission reduction targets by FY2030］^*16
・Scope1+2
63% reduction (base year: FY2015)
・Scope 3
37.5% reduction (base year: FY2015)

^*15 For details, please visit the following website:
Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions
^*16 For details, please visit the following website:
Environment Initiatives | Astellas Pharma Inc.
ESG Data | Astellas Pharma Inc.
^*17 CMO: Contracted Manufacturing Organizations
^*18 Performance of 1st half of FY2023